CALGARY and SAN DIEGO, CA, Nov. 2,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech
company developing REOLYSIN®, an intravenously delivered
immuno-oncolytic virus that activates the innate and adaptive
immune systems to turn 'cold' tumors 'hot', today announced the
appointment of Deborah M. Brown,
B.Sc., M.B.A., to Oncolytics' Board of Directors.
"Ms. Brown's wealth of experience in new product launches and
market expansion will lend valuable insights as we progress
REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics
Biotech. "In addition to successfully leading the launch of a
blockbuster drug in a new therapeutic category, Ms. Brown has
experience in regulatory affairs, research and development and
business development, which will support our clinical development
programs and our pursuit of research collaborations and
commercialization partnerships."
In addition to being a Management Consultant since 2014, Ms.
Brown is currently a Managing Partner at Accelera Canada, a
specialty consultancy firm that assists emerging biopharma ventures
in the United States and
Europe with the development and
implementation of Canadian market strategies. She held
progressively senior roles at EMD Serono from 2000 to 2014,
including Executive Vice President of Neuroimmunology for the
company's U.S. operations, and President and Managing Director of
the company's Canadian operations. In 2012, Ms. Brown was Chair of
the National Pharmaceutical Organization (now Innovative Medicines
Canada) and served on its Board of Directors from 2007 to 2014. She
currently sits on the Boards of Life Sciences Ontario, the
Strategic Executive Advisory Council for Canadian Cancer Trials
Group, and her local SPCA. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the
University of Guelph and completed the
Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University's Kellogg School of
Management.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an intravenously
delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype – turning
'cold' tumors 'hot' – through innate and adaptive immune responses
to treat a variety of cancers. Oncolytics' clinical development
program emphasizes three pillars: chemotherapy combinations to
trigger selective tumor lysis; immuno-therapy combinations to
produce adaptive immune responses; and immune modulator (IMiD)
combinations to facilitate innate immune responses. Oncolytics
is currently planning its first registration study in metastatic
breast cancer, as well as studies in combination with checkpoint
inhibitors and targeted and IMiD therapies in solid and
hematological malignancies. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN® as a
cancer therapeutic; the Company's expectations as to the success of
its research and development programs in 2017 and beyond, the
Company's planned operations, the value of the additional patents
and intellectual property; the Company's expectations related to
the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the
design, timing, success of planned clinical trial programs; and
other statements related to anticipated developments in the
Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.